Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.75 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | CCKAR | P32238 | 1/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19723974 | 0.99 | GLP1R (0.74) | GLP1RLPAR3LPAR1CCKARCCKBR | |
| SCHEMBL24891111 | 0.90 | GLP1R (0.63) | GLP1RCCKARCCKBR | |
| SCHEMBL27327227 | 0.90 | GLP1R (0.62) | GLP1RCCKARCCKBR | |
| SCHEMBL8258329 | 0.89 | GLP1R (0.79) | GLP1RCCKARCCKBR | |
| SCHEMBL29323009 | 0.89 | GLP1R (0.79) | GLP1RCCKARCCKBR | |
| SCHEMBL15360141 | 0.89 | GLP1R (0.79) | GLP1RCCKARCCKBR | |
| SCHEMBL24838647 | 0.89 | GLP1R (0.79) | GLP1RCCKARCCKBR | |
| SCHEMBL23253771 | 0.89 | GLP1R (0.79) | GLP1RCCKARCCKBR | |
| SCHEMBL29322838 | 0.89 | GLP1R (0.79) | GLP1RCCKARCCKBR | |
| SCHEMBL18893454 | 0.89 | GLP1R (0.79) | GLP1RCCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170051034-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170051034-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | GLP1R 1/4885LPAR3 788/4885LPAR1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.